Efficacy of EMG- and EEG-Biofeedback in Fibromyalgia Syndrome: A Meta-Analysis and a Systematic Review of Randomized Controlled Trials
Table 1
Main study characteristics.
Author; country; year; setting; referral or recruitment
Mean age; female %; race %
Diagnosis of
Study population
Treatment group
Control group
Both groups
Outcomes used for meta-analysis latest follow up
screened/ randomized (%); completing therapy (%)
Type of treatment; duration of treatment; at baseline/ completing therapy (%)
Type of treatment; duration of treatment; at baseline/ completing therapy (%)
Comedication allowed; attendance rates (all sessions); side effects; drop out due to side effects in treatment group
Babu et al.; India; 2007; outpatient; not reported [34]
39; 70%; Not reported
criteria
Not reported/30; 30 (100%)
; 6 individual sessions of 45 minutes; 15/15 (100%)
Sham EMG-BFB; 6 individual sessions of 45 minutes; 15/15 (100%)
not reported; not reported; not reported; not reported
Pain 0–10* Sleep VAS 0–10** Fatigue VAS 0–10** Depression VAS 0–10**
Total VAS 0–80*No follow-up
Buckelew et al.; USA; 1998; outpatient; university hospital, private practice [33]
44; 90.8%; not reported
Yunus criteria
240/119 (49.6%); 109 (91%)
EMG-BFB and relaxation; 6-week individual treatment once a week for 1.5–3 hours; 29/27 (93.1%)
Attention control; 6-week individual treatment once a week for 1.5–3 hours; 30/28 (93.3%)
Yes not reported; not reported; not reported
Pain VAS 0–10* Sleep VAS 0–10* Fatigue Depression HRQOL NA 24 months
Ferraccioli et al.; Italy; 1987; outpatient; consecutive patients at an outpatient clinic [35]
57; 100%; not reported
Not exactly specified
Not reported/12; 12/12 (100%)
EMG-BFB; 15 sessions, two sessions a week; 6/6 (100%)
Sham EMG-BFB; 15 sessions; 6/6 (100%)
Allowed; not reported; not reported; none
Pain VAS 0–10 Sleep NA Fatigue NA Fatigue NA Depression NA HRQOL NA No follow-up
Kayiran et al.; Turkey; 2010; outpatient; consecutive patients at an outpatient clinic [39]
32; 100%; not reported
ACR criteria
Not reported/40; 36 completing the first follow-up (90%)
; 20 individual sessions of 30 minutes; 20/18 completing the first follow-up (90%)
Escitalopram (an ) 10 mg/day; 8 weeks; 20/18 completing the first follow-up (90%)
not allowed; not reported; not reported; not reported
Pain VAS 0–10 Sleep NA Fatigue VAS 0–10 Depression ( 0–63) HRQOL FIQ Total VAS 0–80 4 months
Kravitz et al.; USA; 2006; outpatient; at two private practices and via advertisement and self-help groups [36]
46.9; 92%; 92% white
ACR criteria
159/64 (40.3%); 59 (92.2%)
EEG-BFB; 22 sessions; 33/31 (93, 9%)
Sham EEG-BFB; 22 sessions; 31/28 (90.3%)
Morphines, SSRIs, and Benzodiazepines not allowed, other medication allowed; 74% reported side effects of EEG-BFB, e.g. fatigue, headache and sleep problems; not reported
Pain VAS 0–10 Sleep VAS 0–10 Fatigue VAS 0–10 Depression VAS 0–10 HRQOL FIQ Total VAS 0–80** 1 week
Nelson et al.; USA; 2010; outpatient; FMS database and advertisement [38]
51.6; 100%; 88.2% white
ACR criteria
82/42 (51.2%); 34 (81%)
EEG-BFB; 22 sessions; 21/17 (81%)
Sham EEG-BFB; 22 sessions; 21/17 (81%)
Allowed; not reported; none; none
Pain VAS 0–10* Fatigue VAS 0–10* Sleep MOS Sleep NRS 0–100 Depression PHQ 9 HRQOL FIQ Total VAS 0–80 6 months
Van Tulder et al.; the Netherlands; 2001; outpatient; central registry [8]
; 100%; not reported
ACR criteria
(53.4%); 118 (82.5%)
EMG-BFB; 16 sessions; 50/43 (86%)
Treatment as usual; consecutive medical care; 29/28 (96.55%)
Allowed; 88% of patients attended 67% of BFB sessions; 2 patients reported stress due to ; 2 patients
Pain VAS 0–10 Sleep NA Fatigue VAS 0–100 Depression NA HRQOL Total (NRS 0–100) 6 months
FMS: fibromyalgia syndrome; ACR: American College of Rheumatology; EMG-BFB: electromyography biofeedback; VAS: visual analogue scale; HRQOL: health-related quality of life; FIQ: Fibromyalgia Impact questionnaire; The study included 4 different conditions. The analysis was performed with two of these conditions (Biofeedback and attention control); the numbers represent all four groups; NA: not assessed; CES: center for Epidemiological Studies Depression Scale; EEG-BFB: electroencephalography biofeedback (Neurofeedback); SSRI: selective serotonin reuptake inhibitor (an antidepressant); BDI: Beck Depression Inventory; NRS: Numeric Rating Scale; MOS: Medical Outcomes Study Sleep Scale; PHQ 9: Patient Health Questionnaire, In the BFB group; the study included 3 different conditions. The analysis was performed with two of these conditions (biofeedback and treatment as usual control); the numbers represent all three groups. BFB: biofeedback; SIP: sickness impact profile. Note: Studies are presented in alphabetical order.
*Data provided on request.
**Data not provided on request.